- •SM-VAP occurred lately after the onset of mechanichal ventilation.
- •Exposure to carbapenem and carboxy- or ureido-penicillin during the week before VAP and the severity of disease with respiratory and hematological failures were independent risk factors for the SM-VAP occurrence.
- •The prognosis of patients with SM-VAP was poor and not modified by the adequacy of antimicrobial therapy.
- •Antibiotics exposure the week before VAP and the severity of disease were independent risk factors for the SM-VAP occurrence.
Stenotrophomonas maltophilia (SM) is increasingly identified in intensive care unit (ICU). This study aim to identify risk factors for SM ventilator-associated pneumonia (VAP) and whether it affects ICU mortality
Two nested matched case-control studies were performed based in OUTCOMEREA database. The first episodes of SM-VAP patients were matched with two different control groups: VAP due to other micro-organisms (VAP-other) and Pseudomonas aeruginosa VAP (Pyo-VAP). Matching criteria were the hospital, the SAPS II, and the previous duration of mechanical ventilation (MV).
Of the 102 SM-VAP patients (6.2% of all VAP patients), 92 were matched with 375 controls for the SM-VAP/other-VAP matching and 84 with 237 controls for the SM-VAP/Pyo-VAP matching. SM-VAP risk factors were an exposition to ureido/carboxypenicillin or carbapenem during the week before VAP, and respiratory and coagulation components of SOFA score upper to 2 before VAP. SM-VAP received early adequate therapy in 70 cases (68.6%). Risk factors for Day-30 were age (OR = 1.03; p < 0.01) and Chronic heart failure (OR = 3.15; p < 0.01). Adequate treatment, either monotherapy or combination of antimicrobials, did not modify mortality. There was no difference in 30-day mortality, but 60-day mortality was higher in patients with SM-VAP compared to Other-VAP (P = 0.056).
In a large series, independent risk factors for the SM-VAP were ureido/carboxypenicillin or carbapenem exposure the week before VAP, and respiratory and coagulation components of the SOFA score > 2 before VAP. Mortality risk factors of SM-VAP were age and chronic heart failure. Adequate treatment did not improve SM-VAP prognosis.
Abbreviations:VAP (Ventilator–acquired pneumonia), ICU (intensive care unit), SM-VAP (Stenotrophomonas maltophilia ventilator–acquired pneumonia), Others-VAP (Others microorganisms ventilator–acquired pneumonia), Pyo-VAP (Pseudomonas aeruginosa ventilator–acquired pneumonia)
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Infection
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Stenotrophomonas maltophilia–the most worrisome threat among unusual non-fermentative gram-negative bacilli from hospitalized patients: a prospective multicenter study.J Infect. 2012; 64: 391-398
- Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome.Crit Care. 2006; 10: R143
- Stenotrophomonas maltophilia: an emerging opportunist human pathogen.Lancet Infect Dis. 2009; 9: 312-323
- Stenotrophomonas maltophilia - a low-grade pathogen with numerous virulence factors.Infect Dis. 2018; 13: 1-11
- Antimicrobial therapy for Stenotrophomonas maltophilia infections.Eur J Clin Microbiol Infect Dis. 2007; 26: 229-237
- Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections.Antimicrob Agents Chemother. 2014; 58: 176-182
- New strategies against Stenotrophomonas maltophilia: a serious worldwide intrinsically drug-resistant opportunistic pathogen.Expert Rev Anti Infect Ther. 2014; 12 (. Epub 2013 Dec 4): 1-4https://doi.org/10.1586/14787210.2014.864553
- Ventilator-associated pneumonia.Am J Respir Crit Care Med. 2002; 165: 867-903
- Ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacilli in an intensive care unit without carbapenemase-producing Enterobacteriaceae or epidemic Acinetobacter baumannii.Scand J Infect Dis. 2014; 46: 215-220
- Factors associated with mortality in patients with bloodstream infection and pneumonia due to Stenotrophomonas maltophilia.Eur J Clin Microbiol Infect Dis. 2008; 27: 901-906
- Diagnostic and therapeutic management of nosocomial pneumonia in surgical patients: results of the Eole study.Crit Care Med. 2002; 30: 368-375
- Early-onset pneumonia after cardiac arrest: characteristics, risk factors and influence on prognosis.Am J Respir Crit Care Med. 2011; 184: 1048-1054
- Attributable mortality of Stenotrophomonas maltophilia bacteremia.Clin Infect Dis. 2002; 34: 1653-1656
- Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome.PLoS One. 2012; 7: 18
- Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options.Front Microbiol. 2015; 6
- Stenotrophomonas maltophilia ventilator-associated pneumonia. A retrospective matched case-control study.Infect Dis. 2016; 48: 738-743
- Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients.Clin Infect Dis. 2002; 35: 228-235
- Risk factors for mortality in patients with nosocomial Stenotrophomonas maltophilia pneumonia.Infect Control Hosp Epidemiol. 2009; 30: 1193-1202
- Outbreak of Stenotrophomonas maltophilia on an intensive care unit.J Hosp Infect. 2013; 85: 303-307
- Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012.Int J Antimicrob Agents. 2014; 43: 328-334
- Ventilator-associated pneumonia caused by potentially drug-resistant bacteria.Am J Respir Crit Care Med. 1998; 157 (PubMed PMID: 9476869. Epub 1998/02/26. eng): 531-539
- Central venous catheter and Stenotrophomonas maltophilia bacteremia in cancer patients.Cancer. 2006; 106: 1967-1973
- Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature.Future Microbiol. 2009; 4: 1103-1109
- EUCAST expert rules in antimicrobial susceptibility testing.Clin Microbiol Infect. 2013; 19: 141-160
- Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S.maltophilia infections. Antimicrob Agents Chemother. 2010; 54: 2735-2737
- Impact of initial antimicrobial therapy in patients with bloodstream infections caused by Stenotrophomonas maltophilia.Antimicrob Agents Chemother. 2005; 49: 3980-3981https://doi.org/10.1128/AAC.49.9.3980-3981.2005
- Clinical and microbiologic outcomes in trauma patients treated for Stenotrophomonas maltophilia ventilator-associated pneumonia.Pharmacotherapy. 2011; 31: 338-345
- The Association between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria: A Prospective Study.Clin Infect Dis. 2018; 27: 1815-1823
- The Impact of Early Adequate Treatment on Extubation and Discharge Alive of Patients With Pseudomonas aeruginosa-Related Ventilator-Associated Pneumonia.Crit Care Med. 2018; 46: 1643-1648
- Co-infection of Pseudomonas aeruginosa and Stenotrophomonas maltophilia in hospitalised pneumonia patients has a synergic and significant impact on clinical outcomes.Eur J Clin Microbiol Infect Dis. 2017; 36: 2231-2235
- Risk factors for relapse of ventilator-associated pneumonia related to nonfermenting Gram negative bacilli: a case-control study.J Infect. 2008; 56: 319-325
Published online: November 01, 2019
Accepted: October 26, 2019
The manuscript was written on behalf of the OUTCOMEREA study group listed in the appendix.
© 2019 Published by Elsevier Ltd on behalf of The British Infection Association.